secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anixa Biosciences Inc (ANIX)
CIK:        0000715446
Form:       8-K
Filed at:   2023-12-07T23:59:59+00:00
Accession:  0001493152-23-043932
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anixa reports positive Phase 1 breast cancer vaccine data; T-cell responses in 75% of patients
--------------------------------------------------------------------------------

- 16 TNBC patients treated; 12/16 (75%) developed antigen-specific T-cell responses at all dose levels.
- Statistically significant increases in IFNγ (P=0.03) and IL-17 (P=0.0001) over baseline.
- Dose Level 1 determined as immunologic and maximum tolerated dose; no serious adverse events besides injection site irritation.
- Plans to evaluate vaccine with Keytruda in residual disease cohort and in BRCA/PALB2 mutation carriers.
- CEO says data exceeded expectations; Phase 2/3 planning underway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/715446/000149315223043932/0001493152-23-043932-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/715446/000149315223043932/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-043932

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer